DGAP-News: True Leaf Medicine International Ltd

DGAP-News: True Leaf announces Private Placement

DGAP-News: True Leaf Medicine International Ltd. / Key word(s): Capital Increase/Investment True Leaf announces Private Placement

20.10.2016 / 09:21 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Vancouver, BC, October 20, 2016 - True Leaf Medicine International Ltd. (the "Company") (CSE: MJ) (Frankfurt: TLA, WKN: A14NM1) is pleased to announce that it intends to complete a non-brokered private placement of up to 9,523,809 common shares at a price of C$0.21 per common share for aggregate gross proceeds of up to C$2,000,000 (the "Offering").

All or a portion of the Offering may be completed pursuant to Multilateral CSA Notice 45-318 Prospectus Exemption for Certain Distributions through an Investment Dealer ("CSA 45-318") and the corresponding instruments, orders and rules implementing CSA 45-318 in the participating jurisdictions (collectively with CSA 45-318, the "Investment Dealer Exemption"). In order for the Company to be able to rely on the Investment Dealer Exemption, each subscriber must purchase the shares as principal and obtain advice regarding the suitability of the investment from a person that is registered as an investment dealer in the jurisdiction in which the subscriber is resident.

The Company intends to use the proceeds of the Offering as follows: - $750,000 for advertising and marketing costs at retail, wholesale and consumer levels, digital marketing and trade show attendance;

- $750,000 for working capital and the purchase of inventory; and

- $500,000 for new product development, formulation development, pilot trials, contract research and evaluation of potential acquisition targets.

There is no material fact or material change about the Company that has not been generally disclosed. There is no minimum subscription amount for the Offering, and each common share issued pursuant to the Offering will be subject to a four month and one day hold period in accordance with applicable securities laws.

The Company may pay a finder's fee to eligible persons equal to 8% of the gross proceeds raised from applicable subscribers in the Offering either in the form of cash or common shares.

About True Leaf Medicine International Ltd. The Company, through its wholly-owned subsidiary True Leaf Pet Inc., is entering the C$60 billion pet industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Canada and the United States. True Leaf Medicine Inc., a subsidiary of the Company, has also filed an application under Health Canada's Marihuana for Medicinal Purposes Regulations (MMPR) to become a Canadian licensed producer of medicinal marijuana. True Leaf Medicine Inc. has passed through the preliminary and enhanced screening process of Health Canada's review, but must still receive security clearance, pre-licensing approval, and approval to become a licensed producer under the MMPR.

For more information, please see the Company's website at www.trueleaf.com.

Contact: Kevin Bottomley, Director Telephone: +1 778 389 9933 Email: kevin@trueleaf.com Address: 100 Kalamalka Lake Road, Unit 32, Vernon, British Columbia V1T 9G1 Canada

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward- looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

---------------------------------------------------------------------------

20.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: True Leaf Medicine International Ltd. 32 - 100 Kalamalka Lake Road V1T 9 G1 Vernon (BC) Canada Phone: +17783899933 E-mail: kevin@trueleaf.com Internet: www.trueleaf.com ISIN: CA89785C1077, CA89785C1077 WKN: , A0Q3EE Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; Canadian Venture Exchange End of News DGAP News Service ---------------------------------------------------------------------------

513073 20.10.2016